Chronic lymphocytic leukemia: pathophysiology and current therapy

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in Western nations, contrasting with its rarity in Japan.
• Next-generation sequencing has identified numerous mutations in CLL patients, though no disease-specific mutations have been discovered.
• Specific mutations (e.g., TP53, NOTCH1, SF3B, BIRC3) are valuable for risk stratification and predicting prognosis in CLL.

Purpose of the Study:

• To review the current understanding of genetic mutations in CLL.
• To discuss the evolving landscape of CLL treatment strategies.
• To highlight the availability and approval status of key CLL therapeutics in Japan.

Main Methods:

• Literature review of genetic mutations in CLL.
• Analysis of current therapeutic strategies and drug approvals.
• Comparison of treatment accessibility between Western countries and Japan.

Main Results:

• Several mutations are identified in CLL, aiding in prognosis but not specific to the disease.
• Targeted agents like B-cell receptor pathway inhibitors, anti-CD20 antibodies, and Bcl-2 inhibitors represent significant advancements.
• Treatment options differ, with some key drugs unavailable in Japan, while others like ibrutinib and bendamustine are recently approved.

Conclusions:

• Genetic mutations play a crucial role in CLL management and prognosis.
• The therapeutic landscape for CLL is rapidly advancing with novel targeted agents.
• Access to and approval of CLL treatments vary geographically, impacting patient care in different regions.